Navigation Links
PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
Date:2/6/2013

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).  PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with hemophilia.

Currently, factor VIIa therapy is available only as an intravenous (IV) formulation, which can be onerous for patients.  The company will present new data at the EAHAD Congress showing that PROLOR's long-acting Factor VIIa-CTP has demonstrated the potential for subcutaneous (SC) administration in addition to standard IV dosing.  PROLOR researchers believe that a long-acting factor VIIa therapy that could be administered subcutaneously, using a simple injection, would allow children and adults with hemophilia to easily self-administer factor Vlla at home on a prophylactic basis, significantly improving their quality of life. 

Dr. Abraham Havron , CEO of PROLOR, commented, "We have previously presented data in animal models of hemophilia showing that Factor Vlla-CTP demonstrated superiority across key efficacy and safety parameters as compared to current factor VIIa therapy.  The potential for SC administration may represent a major competitive advantage for our long-acting Factor Vlla-CTP, and we expect to initiate a Phase II clinical trial in hemophilia patients in late 2013 or early 2014."

The data will be presented from 5:00-8:00pm local time on February 6, 2013 by Dr. Gili Hart , Director of Pre-Clinical Affairs at PROLOR and head of the company's long-acting clotting factors program.  The European Association fo
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
4. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
5. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
6. Puma Biotechnology Announces Completion of Private Placement
7. Animal Biotechnology - Technologies, Markets and Companies
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
11. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Kindred Biosciences, Inc. ... saving and improving the lives of pets, announced today that ... results on March 12, 2015 after the market close. The ... Time that day. Interested parties may access ... or (484) 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... 03, 2015 Cambridge Semantics, the leading ... technology, today announced that it has been named to ... in Knowledge Management.’ , To create the list ... analysts and system integrators who identify organizations dedicated to ... right information to the right people at the right ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... to their offering. , Gene ... vectors, nonviral vectors and cell therapy with genetically ... of drug delivery and various routes of administration ...
(Date:3/3/2015)... , March 3, 2015 DNA Diagnostics Center ... in the world, celebrates its 20 th anniversary ... , DDC is a consumer services company that focuses ... employs over 200 associates and generates a significant portion ... over 120 countries. Peter Vitulli ...
Breaking Biology Technology:Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 2DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 3
... Conn., Feb. 14 Biodel Inc. (Nasdaq:,BIOD) today reported ... The net loss for the quarter was $11.0 million ... pivotal Phase III clinical trials of,VIAject(TM) positions us to ... the FDA by the end of 2008," stated Dr. ...
... Product that Meets Regulatory &, Health Issues ... ORLANDO, Fla., Feb. 14 Valensa International ... the extraction of,Haematococcus pluvialis for the manufacture of ... of recently growing demand for a,high-quality astaxanthin in ...
... 2007 Launch; Positioned for Expanded Growth in ... U.S. and International Markets, Fourth Quarter and 2007 Financial Highlights:, ... compared to net product sales of $21.8 million in Q3 2007., ... a GAAP net loss of $20.1 million, or $0.55 per share, ...
Cached Biology Technology:Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 7Valensa Expands Astaxanthin Extraction Capacity 2Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... threatened by exotic species of the moon jellyfish being ... Using genetic data and computer simulations of ocean currents ... South Wales and the University of California, Davis, have ... naturally, according to a report in today's Proceedings of ...
... has discovered how a gene that suppresses the development of ... way to treatments based on the function of the gene. ... Hormel Institute in Austin, Minn., have applied for a patent ... July 10 in the journal Nature Structural & Molecular Biology. ...
... suggested that ancient Neanderthals might have had an accelerated childhood ... based on a new assessment by researchers from Ohio State ... found that the rate of tooth growth present in the ... different populations of modern humans. , And since the ...
Cached Biology News:Ships bring alien jellyfish invaders to our shores 2Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: